解开:一种蛋白质,许多治疗方法
Courtney Lane-Donovan1, Adam L Boxer1
1Memory and Aging Center, Department of Neurology, University of California, San Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA.
概括
陶蛋白功能障碍导致神经退行性疾病,如阿尔茨海默氏症. 尽管有大量的药物开发工作,但没有批准针对的治疗方法,这需要重新评估当前的研究和临床试验策略.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 陶生物与遗传学
背景情况:
- 陶病是一种20多种成人神经退行性疾病的组.
- 它的特征是tau蛋白的功能障碍和积累.
- 阿尔茨海默氏症,前性痴呆症和渐进性超核性影响全球数百万人.
研究的目的:
- 审查目前对生物和遗传学的理解.
- 分析过去和正在进行的病症临床试验的背景.
- 确定缺乏批准的定位治疗方法的原因.
主要方法:
- 关于tau生物学,遗传学和临床试验数据的文献综述.
- 分析当前和失败的治疗开发策略.
- 综合信息,提出新的治疗开发途径.
主要成果:
- 尽管进行了广泛的研究,但尚未获得临床批准的定向疗法.
- 目前的tau病理模型和非临床方法可能需要重新评估.
- 已经确定了几种治疗失败的潜在原因.
结论:
- 对tau生物学和临床试验结果进行批判性审查是必不可少的.
- 需要对非临床模型和试验设计采取新的方法.
- 人们对未来的病疗法发展充满乐观.
相关概念视频
01:22Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
01:26Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487